HOOKIPA Pharma Inc. (HOOK)
| Market Cap | 15.30M +52.3% |
| Revenue (ttm) | 9.35M -82.5% |
| Net Income | -73.31M |
| EPS | -5.85 |
| Shares Out | 12.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 357 |
| Average Volume | 11,582 |
| Open | 1.130 |
| Previous Close | 1.190 |
| Day's Range | 1.130 - 1.190 |
| 52-Week Range | 0.811 - 1.770 |
| Beta | 0.83 |
| RSI | 64.50 |
| Earnings Date | Mar 26, 2026 |
About HOOKIPA Pharma
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cance... [Read more]
Financial Performance
In 2024, HOOKIPA Pharma's revenue was $43.95 million, an increase of 118.32% compared to the previous year's $20.13 million. Losses were -$43.50 million, -46.67% less than in 2023.
Financial StatementsNews
Hookipa Pharma announces sale of oncology assets to NeoTrail Therapeutics
HOOKIPA Pharma (HOOK) announced the sale of its immuno-oncology related assets, consisting primarily of the HB-200 and HB-700 development programs, to NeoTrail Therapeutics. The purchase price remains...
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price Next-generation therapeutic cancer vaccines...
Hookipa Pharma completes sale of HBV, HIV assets to Gilead
HOOKIPA Pharma (HOOK) announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences…
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and cer...
Hookipa Pharma to delist shares from Nasdaq
Hookipa Pharma (HOOK) announced its intention to voluntarily delist from Nasdaq and to deregister its common stock.
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the t...
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIO...
Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial
HOOKIPA Pharma (HOOK) announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 participants enrolled across five sites in the…
Hookipa Pharma downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Hookipa Pharma (HOOK) to Neutral from Buy without a price target after the company entered into a non-binding agreement with Poolbeg for an all-stock acquisition of Poolbeg.
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
HOOKIPA Pharma Inc - FORM 8 (OPD)
NEW YORK and VIENNA, Austria, Jan. 08, 2025 (GLOBE NEWSWIRE) -- FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the “Code”) 1. KEY...
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immu...
HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Hookipa Pharma to acquire Poolbeg Pharma
The boards of directors of Hookipa Pharma (HOOK) and Poolbeg Pharma announced that they have entered into non-binding discussions for an all-share acquisition by Hookipa of Poolbeg to create a…
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Hookipa Pharma downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Hookipa Pharma (HOOK) to Sector Perform from Outperform with a price target of $2, down from $48. The company recently announced a restructuring, including an 80% workforce…
Hookipa Pharma price target lowered to $7 from $24 at JMP Securities
JMP Securities lowered the firm’s price target on Hookipa Pharma (HOOK) to $7 from $24 and keeps an Outperform rating on the shares. Hookipa announced Wednesday that it will reduce…
Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program
In a regulatory filing on Wednesday, Hookipa Pharma (HOOK) announced that on November 18, the company approved a plan to continue to improve its cost structure and operating efficiency, which…
Hookipa Pharma price target lowered to $48 from $50 at RBC Capital
RBC Capital lowered the firm’s price target on Hookipa Pharma (HOOK) to $48 from $50 and keeps an Outperform rating on the shares. Hookipa Pharma and its new management are…
Hookipa Pharma reports Q3 EPS ($1.10), consensus ($1.90)
Reports Q3 revenue $4.7M, consensus $4.95M…”HOOKIPA made excellent progress across each program in our pipeline in the third quarter,” said Malte Peters, MD, Chief Executive Officer of HOOKIPA. “We ad...
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell respo...
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 Society of Immunotherapy of Cancer (SITC)...
Hookipa Pharma doses first patients with eseba-vec
HOOKIPA Pharma (HOOK) announced that researchers at Memorial Sloan Kettering Cancer Center, MSKCC, have dosed the first patients in an investigator initiated trial, IIT, of eseba-vec, HOOKIPA’s human ...
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service
Hookipa Pharma to present HB-700 dataset at RAS-Targeted Drug Development Summit
HOOKIPA Pharma announced that the Company will present preclinical data related to the HB-700 program for the treatment of KRAS mutated cancers at the 6th Annual RAS-Targeted Drug Development Summit…